College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Division of Infectious Diseases, Northwestern University, Chicago, IL, USA.
Ageing Res Rev. 2024 Aug;99:102400. doi: 10.1016/j.arr.2024.102400. Epub 2024 Jun 28.
It has been four years since long COVID-the protracted consequences that survivors of COVID-19 face-was first described. Yet, this entity continues to devastate the quality of life of an increasing number of COVID-19 survivors without any approved therapy and a paucity of clinical trials addressing its biological root causes. Notably, many of the symptoms of long COVID are typically seen with advancing age. Leveraging this similarity, we posit that Geroscience-which aims to target the biological drivers of aging to prevent age-associated conditions as a group-could offer promising therapeutic avenues for long COVID. Bearing this in mind, this review presents a translational framework for studying long COVID as a state of effectively accelerated biological aging, identifying research gaps and offering recommendations for future preclinical and clinical studies.
自首次描述 COVID-19 幸存者所面临的长期后果——长新冠以来，已经过去了四年。然而，这种疾病仍在不断破坏越来越多的 COVID-19 幸存者的生活质量，而目前既没有经过批准的治疗方法，也没有针对其生物学根本原因的临床试验。值得注意的是，长新冠的许多症状通常随着年龄的增长而出现。利用这一相似性，我们假设衰老生物学（旨在针对衰老的生物学驱动因素，以预防与年龄相关的疾病）可以为长新冠提供有前途的治疗途径。考虑到这一点，本综述提出了一个将长新冠作为一种有效加速生物学衰老状态进行研究的转化框架，确定了研究空白，并为未来的临床前和临床研究提供了建议。
